Konstantin Hristov Dragnev MD

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Geisel School of Medicine at Dartmouth, Associate Director for Clinical Research, Norris Cotton Cancer Center

Join to View Full Profile

1 Medical Center DrLebanon, NH 03756
Phone+1 603-650-6345
Fax+1 603-650-9496

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1998 - 1999
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1998
Baylor College of MedicineResidency, Internal Medicine, 1993 - 1996
Medical University of Sofia FOMClass of 1987

Certifications & Licensure

NH State Medical License 1999 - 2025
MI State Medical License 1996 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Mar 01
Completed
Phase 1
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Study of Tarceva and Targretin in Stage I-II Lung Cancer Start of enrollment: 2005 Dec 01
Completed
Not Applicable
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer Start of enrollment: 2009 Mar 01
Completed
Not Applicable
Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer Start of enrollment: 2004 Sep 01
Terminated
Phase 1, Phase 2
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract Start of enrollment: 2003 Apr 01
Completed
Phase 1
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
COMPLETED
PHASE1, PHASE2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
ACTIVE_NOT_RECRUITING
PHASE3
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery Start of enrollment: 2014 Sep 01
Terminated
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah
Journal for Immunotherapy of Cancer. 2025-02-04
4 citations
Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
David Kozono, Xing Hua, Michael C Wu, Khaled A Tolba, Saiama N Waqar
Journal of Thoracic Oncology. 2024-12-01
Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
Sai Yendamuri, Konstantin H Dragnev
Cancer Prevention Research. 2024-09-04

Press Mentions

Pragmaticism in Cancer Clinical TrialsJune 1st, 2024
SWOG S2302 Pragmatica-Lung Study Opens to Enrollment, a Model for Easier, More Representative Clinical TrialsApril 12th, 2023
New Drug Combination Lengthened Survival for Some with Lung CancerJune 3rd, 2022
Join now to see all